This mechanism could be confirmed in human BCC, where patient biopsies taken before, during and after HH inhibitor therapy showed that GLI1 expression had nearly completely vanished, while small tumorigenic lesions expressing LGR5 persisted [119]. The gene discussed is LGR5; the disease is skin basal cell carcinoma.